Stocks
TriSalus Life Sciences, Inc.TLSI
NASDAQHealthcareBiotechnology$3.72
Price as of · delayed, not real-time
A clinical-stage oncology company developing investigational therapies that combine its proprietary Pressure-Enabled Drug Delivery (PEDD) platform with immunotherapies to treat liver and pancreatic tumors. The company's lead candidate, TAVO-103, is in Phase 1/2 trials for uveal melanoma liver metastases, and investors track it for its potential to address high unmet need in hard-to-treat cancers.
52W Range: $2.20-$7.95
Congressional Interest in TriSalus Life Sciences, Inc. (TLSI)
No congressional trades have been disclosed for TriSalus Life Sciences, Inc. (TLSI) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TLSI?
No congressional trades found for this stock.